196 related articles for article (PubMed ID: 24416061)
21. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
22. Dermatomyositis: Clinical features and pathogenesis.
DeWane ME; Waldman R; Lu J
J Am Acad Dermatol; 2020 Feb; 82(2):267-281. PubMed ID: 31279808
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X
Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170
[TBL] [Abstract][Full Text] [Related]
24. Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients.
Kang EH; Kuwana M; Okazaki Y; Lee EY; Lee YJ; Lee EB; Song YW
Mod Rheumatol; 2014 Nov; 24(6):945-8. PubMed ID: 24670134
[TBL] [Abstract][Full Text] [Related]
25. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
[TBL] [Abstract][Full Text] [Related]
26. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome.
Schilders G; Egberts WV; Raijmakers R; Pruijn GJ
Arthritis Rheum; 2007 Jul; 56(7):2449-54. PubMed ID: 17599775
[TBL] [Abstract][Full Text] [Related]
27. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation.
Aggarwal R; Oddis CV; Goudeau D; Fertig N; Metes I; Stephens C; Qi Z; Koontz D; Levesque MC
Rheumatology (Oxford); 2014 Mar; 53(3):433-7. PubMed ID: 24255164
[TBL] [Abstract][Full Text] [Related]
28. [Dermatomyositis-specific antibodies].
Bodoki L; Nagy-Vincze M; Griger Z; Dankó K
Z Rheumatol; 2015 May; 74(4):363-9. PubMed ID: 25644067
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in dermatomyositis-specific autoantibodies.
Fujimoto M; Watanabe R; Ishitsuka Y; Okiyama N
Curr Opin Rheumatol; 2016 Nov; 28(6):636-44. PubMed ID: 27533321
[TBL] [Abstract][Full Text] [Related]
30. Recombinant 52 kDa Ro(SSA) ELISA detects autoantibodies in Sjögren's syndrome sera that go undetected by conventional serologic assays.
McCauliffe DP; Wang L; Satoh M; Reeves WH; Small D
J Rheumatol; 1997 May; 24(5):860-6. PubMed ID: 9150073
[TBL] [Abstract][Full Text] [Related]
31. Validation of anti-Mi2 autoantibody testing by line blot.
Pinal-Fernandez I; Pak K; Casal-Dominguez M; Hosono Y; Mecoli C; Christopher-Stine L; Mammen AL
Autoimmun Rev; 2020 Jan; 19(1):102425. PubMed ID: 31734399
[No Abstract] [Full Text] [Related]
32. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
33. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis.
Labrador-Horrillo M; Martinez MA; Selva-O'Callaghan A; Trallero-Araguas E; Balada E; Vilardell-Tarres M; Juárez C
J Immunol Res; 2014; 2014():290797. PubMed ID: 24741583
[TBL] [Abstract][Full Text] [Related]
34. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease.
Sato S; Hoshino K; Satoh T; Fujita T; Kawakami Y; Fujita T; Kuwana M
Arthritis Rheum; 2009 Jul; 60(7):2193-200. PubMed ID: 19565506
[TBL] [Abstract][Full Text] [Related]
35. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
[TBL] [Abstract][Full Text] [Related]
36. Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara.
Petri MH; Satoh M; Martin-Marquez BT; Vargas-Ramírez R; Jara LJ; Saavedra MA; Cruz-Gonzalez C; Andrade-Ortega L; Vera-Lastra O; Salazar-Páramo M; Prieto-Parra RE; Gonzalez-Lopez L; Gamez-Nava JI; Ramírez-Sánchez HU; Chan JY; Ross SJ; Chan EK; Vázquez-Del Mercado M
Arthritis Res Ther; 2013 Apr; 15(2):R48. PubMed ID: 23557279
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
38. Establishment of an ELISA to detect anti-glycyl-tRNA synthetase antibody (anti-EJ), a serological marker of dermatomyositis/polymyositis and interstitial lung disease.
Hane H; Muro Y; Watanabe K; Ogawa Y; Sugiura K; Akiyama M
Clin Chim Acta; 2014 Apr; 431():9-14. PubMed ID: 24508626
[TBL] [Abstract][Full Text] [Related]
39. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.
Gunawardena H; Wedderburn LR; Chinoy H; Betteridge ZE; North J; Ollier WE; Cooper RG; Oddis CV; Ramanan AV; Davidson JE; McHugh NJ;
Arthritis Rheum; 2009 Jun; 60(6):1807-14. PubMed ID: 19479859
[TBL] [Abstract][Full Text] [Related]
40. Detection of autoantibodies to ribosomal P protein using recombinant autoantigen in a quantitative immunoassay.
Gordon TP; Jovanovich SA; Sykes P; Bradley J; Roberts-Thomson PJ
Rheumatol Int; 1990; 10(3):99-102. PubMed ID: 2392641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
